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Abstract
Craniocerebral aspergillosis is a rare but dangerous
central nervous system infection. The infection has a
spectrum of presenting features, mostly affecting
immunocompromised individuals. The incidence appears to
be on the rise that has been especially observed in the
immunocompetent population. A high index of suspicion, a
comprehensive understanding of the infectious process and
advanced laboratory and radiological diagnostic techniques,
allow early diagnosis. Surgery, followed by systemic anti-
fungal medications, remains the cornerstone of management.
Early administration of empirical anti-fungal agents along
with immunomodulators may further improve prognosis.
Immunocompetent patients tend to have better outcomes as
compared to those who are immunocompromised. Patients
with intradural disease carry the worst prognosis. 
Introduction
Aspergillosis disseminating to the central nervous
system (CNS), is amongst the most serious sequelae of
opportunistic fungal infections. Primary sites of aspergillus
infection are the lungs in immunosuppressed and paranasal
sinuses in immunocompetent individuals. The CNS may be
involved as a primary site, but more commonly it is involved
secondarily through haematogenous spread or as a result of
direct invasion from adjacent structures. In fact, brain is the
second commonest organ to be secondarily affected by
invasive aspergillosis. Primary CNS infection may
occasionally follow gastrointestinal or skin infections and
rarely may occur without a history of an extra cranial source.1
CNS aspergillosis has been considered a rare disease,
accounting for less than five percent of all CNS infections;
although recently there seems to be a rise in their incidence.2
The reason behind this rise could be the increasing number of
immunocompromised individuals due to the growing
epidemic of acquired immunodeficiency syndrome (AIDS),
chronic granulomatous diseases, autoimmune diseases or due
to the rising population of patients having undergone solid
organ transplants and consequently on lifelong
immunosuppressive therapy. The widespread availability of
neuroimaging (CT and MRI) leading to earlier radiological
diagnosis in these patients, and thus earlier referrals to
neurosurgical centers could also be a contributing factor to
the rising incidence. Recently, a peculiar rise in the incidence
of craniocerebral fungal infections has been noted in
immunocompetent persons, or who have been termed the
"apparently immunocompetent" hosts.3 These cases are
unique as they exhibit atypical clinical and radiological
features making the diagnosis all the more difficult and
causing delay in definitive management. Treatment success is
dependent on early diagnosis and aggressive, focused
management. This approach has recently lead to relatively
encouraging results. The main differential diagnosis of these
lesions are brain tumours (both primary and metastatic),
intracranial abscesses, and intracranial tuberculomas.
Pathophysiology:
Aspergillus is a ubiquitous fungus in soil, water,
decaying vegetation and organic debris, and was recognized
to be pathogenic in humans as early as the year 1847. The
organism is characterized by spore forming septate hyphae
which show dichotomous branching, microscopic findings
considered diagnostic for the disease.4 It also possesses an
aerial hyphal stalk harbouring asexually produced conidia,
which is the infective form of the organism and is inhaled by
the human hosts. This, along with the fact that Aspergillus
spores are commensals in the respiratory tract and external
auditory canal, makes it understandable that the maxillary
sinus and lungs are the most common sites of primary
Aspergillus infection. 
Among the 19 disease-causing subtypes in the genus
Aspergillus, A. fumigatus is the most commonly identified
human pathogen, although A. flavus, A. niger and A. oxyzae
are also seen. A. flavus has been cultured frequently from
immunocompetent hosts and is the commonest cause of
fungal sinusitis in these patients.2 The incidence is especially
high in patients from hot and dry areas such as Saudi Arabia,
and the Indian subcontinent where it is the most frequently
isolated species in cultures of invasive aspergillosis. Once
activated, the pathogens may spread to the brain through one
of two routes, either invading the cranium directly through
the bone; or through haematogenous metastases. Once inside
the cranium, the disease may remain entirely extradural,
which is the commonest location; or intradural, or it may be
present across both sides of the dura. Alternatively, it may just
involve the blood vessels or the meninges. The mechanism of
damage at the cellular level in cerebral Aspergillus lesions is
also complex and and has been shown to be due to secretion
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of various necrotizing factors with toxic and lytic activity
towards neurons and glial cells. Studies on these toxic factors
reveal that A. fumigatus and A. terreus produce small, heat-
stable components whereas the toxic activity of A. niger is
triggered by a high molecular mass factor which can be
inactivated by heat. The active component of A. flavus has a
molecular mass similar to that of A. niger but is heat-stable.5
Secretion of these necrotizing factors might contribute to
brain lesions in patients with cerebral aspergillosis.5
The clinical manifestations and disease severity are
dictated by the immunologic state of the patient. In
immunocompromised patients, single or multiple abscesses
with marked vascular invasion, with or without thrombosis, is
the hallmark of cerebral Aspergillosis on pathologic
examination. Aspergillus has a tendency to invade vessels
producing a necrotizing angiitis leading to secondary
thrombosis with or without haemorrhage. Fungal hyphae are
found in large, intermediate and small blood vessels with
invasion through vascular walls into adjacent tissue. The
large arteries most commonly involved are the anterior and
middle cerebral arteries. Evolving haemorrhagic infarcts later
convert into septic infarcts with associated abscesses and
cerebritis. In immunocompetent hosts, the response differs
and a reactive mass forms around the infection in an attempt
to limit the spread. This reactive mass is composed of a thick
fibrous capsule surrounded by gliotic brain tissue, and may
contain within its confines varying consistency of tissues
depending upon the state of infection.5
In purulent lesions, pus is seen in the centre of the
abscesses with abundant polymorphs at the periphery.
Purulent lesions can be chronic and may show a tendency
towards fibrosis and granuloma formation, consisting of
lymphocytes, plasma cells, and fungal hyphae.5 In summary,
brain abscess, epidural abscess, vasculitis and stroke-like
illness are manifestations of CNS aspergillosis in the
immunocompromised, whereas the immunocompetent
generally develop granulomatous masses and meningitis.6
Presentation: 
The overwhelming bulk of literature on aspergillosis
is regarding immunocompromised hosts. Notable case series
of craniocerebral aspergillosis occurring in apparently
immunocompetent hosts have so far been reported mainly
from India, Sudan, Pakistan, Saudi Arabia, UAE, and few
other African countries. On the contrary similar publications
from West are largely confined to isolated case reports.2 The
reason for this demographic difference is not clear, and a
plausible explanation may be the hot, dry climate and low
socioeconomic status in the above-mentioned regions, which
favour the growth of aspergillus.2,7
Classically, craniocerebral aspergillosis should be
considered in any patient known or suspected to be
immunocompromised, presenting with signs, symptoms and
radiological features suggestive of a space-occupying lesion
with or without preceding history of nasal blockade and/or
discharge. Multiple authors have described a variety of
presenting symptoms such as nasal stuffiness, headache, peri-
orbital pain, vomiting, convulsions, hemiparesis, cranial
nerve deficits (diplopia/ anosmia), proptosis, sensory
impairment, dysarthria, lethargy, impaired consciousness,
seizures, fever, and rarely, ear discharge.8 In patients with
paranasal sinus disease, orbital extension with proptosis,
ophthalmoplegia, visual deterioration (which may lead to
total monocular blindness), and chemosis may occur. There
are various clinical syndromes associated with fungal
infections of the CNS and can involve most part of the
neuroaxis.9 These largely depend on the pathological reaction
elicited by the fungus in the host which varies with the
virulence of the organism, the antigen makeup of the species
and the immune status of the host. They can occur alone or in
combination and comprise of meningitis, intracranial mass
lesions, skull-base syndrome, rhinocerebral syndrome, stroke
syndrome and spinal syndrome. Skull-base syndromes
include orbital apex syndrome, cavernous sinus syndrome,
proptosis with or without ocular palsy, polyneuritis cranialis
and orbito-cranial syndromes. In one study of patients
suffering from CNS aspergillosis, 64 out of 89 patients
presented with skull base syndromes.10 The disease is usually
slowly progressive and symptoms may persist for months.
Alternatively, patients may also present acutely with cerebral
infarctions or haemorrhage, a relatively uncommon
manifestation of vascular invasion of the fungus.11 Stroke
may also be due to Aspergillus endocarditis leading to
embolic stroke.10
Laboratory Diagnosis: 
Craniocerebral Aspergillosis is difficult to diagnose
on laboratory based tests alone as blood cultures and even
cerebrospinal fluid (CSF) cultures are frequently negative.
Other serologic tests such as double diffusion counter
immuno-electrophoresis, immuno-fluorescence, or enzyme-
linked immuno-sorbent assay may be helpful in arriving at a
diagnosis but are rarely performed. Detection of aspergillus
galactomannan, a carbohydrate component of the cell wall of
Aspergillus, in urine, CSF or serum, through the above
mentioned techniques has moderate accuracy for diagnosis of
invasive aspergillosis in immunocompromised patients. The
test is more useful in patients who have haematological
malignancy or who have undergone haematopoietic cell
transplantation.6 Several authors have attempted to diagnose
aspergillosis on the basis of CSF specimen; however, the
findings have been inconsistent.11 Even if the CSF is positive,
typically only a small number of fungal cells are present in
CSF and a positive culture may only be obtained if a rather
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large volume of CSF (preferably 5 milliliters or more) is
repeatedly cultured. CSF analysis findings are usually non-
specific for fungal disease. These include elevated cell
counts, showing pleocytosis, elevated proteins and decreased
glucose.11 Antibody detection in serum or CSF is also not
shown to be useful. It has been found that detection of
Aspergillus DNA in CSF samples is possible and has the
potential to improve diagnosis of cerebral aspergillosis.12,13
In order to obtain a positive polymerase chain reaction (PCR)
result, either fungal cells or fungal deoxyribonucleic acid
(DNA) should be present in the CSF sample. Unfortunately,
number of cells present in CSF specimen is extremely low,
and rate of clearance of DNA from CSF is also unknown. So
even if the PCR assay is very sensitive, it still may not be
positive. The yield of PCR may be comparatively high in
cases of disseminated invasive aspergillosis and cerebral
abscesses. However, we do not recommend the use of CSF in
the diagnosis of cerebral aspergillosis as obtaining a CSF
sample through lumbar puncture in a patient harboring an
intracranial space occupying lesion and having raised
intracranial pressure may be dangerous. Serologic tests are
not considered of much help in reaching a diagnosis; for even
a negative result does not exclude the disease. There is also
the issue of availability of these tests. These tests may be
useful for follow up in patients tested positive prior to
intervention (medical or surgical), although in our
experience, clinical status alone is a highly reliable indicator
of treatment outcome. Whenever possible, diagnosis should
be based on a histopathological specimen. A peri-operative
squash smear or frozen section seems to us a much better
means of identifying the pathology and instituting early
pharmacotherapeutic interventions and it is strongly
recommended that it be carried out in all patients with
suspected aspergillus infection.14
Radiological Diagnosis: 
The findings in computed tomography (CT) scan and
magnetic resonance (MR) imaging are frequently minimal or
absent in the hyperacute stage of CNS aspergillosis.15 Later,
there may be multiple irregular lesions with infarction or
haemorrhage in a random distribution owing to the
angioinvasive nature of the disease.16 Cerebral aspergillosis
basically presents with four principal neuroimaging findings:
areas consistent with infarction; ring-enhancing lesions
consistent with abscess formation following infarction; dural
or vascular infiltration originating from paranasal sinusitis or
orbital involvement; and intracranial (intra or extra-axial)
space occupying lesions.17 On CT scanning the lesions are
characteristically hyper-dense with mass effect and may or
may not show contrast enhancement. Calcifications within
the fungal mass may also be present. Abscesses demonstrate
ring and homogenous enhancement, mass effect, low
absorption areas, and slight or no contrast enhancement. On
MR imaging, the classical description is that of an irregular
space occupying mass lesion having hypo- to isointense
signals on T1-weighted images with either bright
homogenous enhancement on post-gadolinium T1 weighted
images or ring enhancement pattern. Extremely low signals
on T2-weighted images are also frequently seen. The
isointensity has been described to be due to coagulative
necrosis of brain tissue secondary to fungal involvement of
vessels, a finding that has been histologically proven. T2-
hypointense zones within the wall of cerebral aspergillus
lesions have also been attributed to dense population of
aspergillus hyphal elements and the presence of haemorrhage
in the capsule but none of the features are specific for
intracranial aspergillus infections. Another explanation for
the zones of low T2 signal intensity is the presence of iron,
manganese, and magnesium in the fungal concretions.18 This
was studied in vitro and a correlation with the concentration
of paramagnetic elements within aspergillus colonies and
intensity of signals was found.19 The paramagnetic elements
are essential for the hyphal growth, especially iron and
magnesium. Also, aspergillus abscesses have been shown to
contain a dense population of hyphal elements at the
periphery, compared to a relative paucity of fungal elements
at the centre, features that likely contribute to the distinct
peripheral T2 hypo intensity.20 The presence of a hypo
intense ring in immunocompromised patients has been
associated with increased risk for haemorrhage, which occurs
in roughly 25% of lesions.21 The MR imaging finding of a
low signal intensity zone surrounded by a thick perimeter of
enhancement should suggest the diagnosis of a fungal
granuloma caused by the hyphal form of the organism. The
thick irregular wall of the mass on MR images indicates a
competent host defense mechanism that is attempting to
isolate or encapsulate the offending organisms.
Recently, diffusion-weighted imaging (DWI) and
magnetic resonance spectroscopy features of CNS
aspergillosis have been presented.22 A high DWI signal
character can be present in septic lesions and this finding can
be explained by the contents of the abscess cavity. Fungal
abscesses exhibit centrally restricted diffusion due to
inflammatory cells, necrotic tissue and protein rich
exudates.16 However, in the case of a small lesion without
contrast enhancement but hyperintense signal on DWI, it is
not possible to differentiate between an infected focus and a
small infarct. The differential diagnosis of multiple brain
lesions in an immunocompromised patient includes
lymphoma, metastatic disease, septic emboli, tuberculomas
and multiple infarcts. It has been shown that aspergillosis
characteristically involves the basal ganglia, indicating a
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preference for lenticulostriate and thalamoperforator vessels,
while corticomedullary involvement is typically less
pronounced.23 The apparent affinity of CNS aspergillosis for
perforating artery distributions is most likely due to the
invasive character of Aspergillus within the walls of the larger
parent arteries subsequently compromising the origins of the
perforating arteries. Pyogenic infection and thrombotic
infarction generally do not involve the corpus callosum.24
Temporal and frontal lobes are common sites for
granulomas.25
Medical Management:
For a long time, the standard therapeutic regimen for
cerebral aspergillosis following surgery remained
intravenously administered amphotericin B combined with,
or followed by, flucytosine or itraconazole.2 Since the
introduction of itraconazole, the first azole with significant
activity against aspergillus, many clinical trials have proven
its efficacy.26,27 In addition to efficacy, other advantages of
itraconazole therapy compared with amphotericin B are that
it is less toxic and thus better tolerated although it shows
variable and inconsistent absorption in some patients. Two
newer parenteral antifungal medications (echinocandins)
caspofungin and micafungin are also under scrutiny.
However, all of the aforementioned medications are used
mainly as adjuncts to surgical management, as despite
improving outcomes compared to control groups, these show
relatively poor penetration into the CNS. A newer triazole,
voriconazole, is becoming increasingly popular. In several
studies, and one large randomized trial conducted recently,
voriconazole has proven to be more effective and less toxic
than amphotericin B, and has since become the first line
treatment of aspergillosis.28 Recently, a very well conducted
study based on an experimental murine model of CNS
aspergillosis established within 5-week old male CD-1 mice
has been published.29 The investigators tested the relative
efficacy of a number of anti-fungal medications, both as
monotherapy, and in combination, using suboptimal as well
as optimal-dose combination therapy. The study supported
the potential of combination therapy as a mechanism to
improve the outcome in CNS aspergillosis, showing that
combination of sub-optimal doses of liposomal amphotericin
B and voriconazole given concurrently was significantly
efficacious in comparison with either monotherapy. 
A few anecdotal reports have been published that
describe treatment with intracavitary amphotericin B.26,30
There may be some theoretical advantage in the
administration of granulocye monocyte colony stimulating
factors (GMCSF) to enhance neutrophil, monocyte and
macrophage antifungal activity in vivo.31 Recombinant γ-IFN
can be given to improve the antifungal properties of
polymorphonuclear cells and helper T cells by tilting their
activities towards a Th1 response and inducing neutrophil-
mediated fungal hyphal damage and also indirectly through
tumor necrosis factor and macrophage inflammatory protein
1α.31 However, these potential therapeutic strategies have not
been tested clinically. It may be recalled here that almost all
the literature on intracranial aspergillus infections in
immunocompetent patients, describes the hosts as
"apparently immunocompetent". It is possible that these
"immunocompetent" patients may be suffering from sub-
clinical qualitative, cellular or sub-cellular immune
deficiency that is either unrecognized or as yet, poorly
characterized. Such patients may benefit from these immuno-
modulators and with the exception of high cost of these
medications, there does not seem to be much harm in their
routine administration to these patients. 
Surgical Management: 
There are no specific treatment recommendations for
intracranial aspergillosis, as detailed data on patient survival
is only available from case reports and case series.26,27
However, despite newer, safer and more effective anti-fungal
medications, the consensus is that the cornerstone of
treatment remains surgical excision, a standard based largely
on reports of personal experience; and more recently on the
basis of  a multifactorial risk analysis done by Schwartz et al
on the data of a study population comprising mainly of
immunocompromised patients on voriconazole therapy,
which suggested improved outcomes in patients who had
undergone neurosurgical intervention.27 Besides, there are
very few reports of patients surviving CNS aspergillosis on
medical treatment alone. It cannot be over emphasized that
surgical excision must always be followed by aggressive
antifungal chemotherapy to achieve best response.7
As compared to radical surgical intervention, sub-
radical excision aimed at establishing diagnosis and reducing
disease burden followed by systemic antifungal therapy
seems to be a better course of action.3 This approach helps to
minimize long-term neurological deficits that may arise as a
result of radical excision, particularly in eloquent areas.
However, when faced with a surgically removable lesion in a
noneloquent area, the best plan would be to perform complete
excision. Sub-radical resection may be reserved for lesions
which are only partially resectable. Obviously, in a lesion
occupying an eloquent area, where iatrogenic permanent
neurological deficits seem inevitable even if sub-radical
excision is attempted, a biopsy would suffice.
A similar approach is advisable in case of cerebral
aspergillus abscesses. These should be excised completely if
there is no risk of further neurological deficits as complete
excision has been shown to improve outcome. Even
lobectomy, in patients with a single aspergillus abscess is an
acceptable surgical option when noneloquent areas of the
brain are involved. On the other hand, when eloquent brain
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areas are found to harbour an aspergillus abscess, aspiration
may be the only surgical option which may be done more
precisely under neuronavigation or stereotactic guidance,
especially if the abscesses are deep-seated. This is not the
optimal treatment option but may be considered as last resort
as it is not curative, but may reduce disease burden. Instances
where the nasal passages are suspected to be involved, there
should be a thorough debridement of nasal passages, thereby
depriving the fungus of a potential microaerophilic
environment otherwise suitable for its proliferation.
Results and Complications: 
Beside the general complications anticipated after
major cranial surgeries, and the adverse effects described for
the antifungal medications, some specific complications
reported for these patients include massive anaphylaxis,
meningitis, mycotic aneurysm formation, intracerebral
haemorrhage, subarachnoid haemorrhage and hydrocephalus.
Hydrocephalus is usually of communicating type, although
non-communicating type may also occur. Perhaps the two
most catastrophic complications, both unusual in etiology,
are; widespread multifocal dissemination in the brain
parenchyma/ ventricles and vascular infarcts involving major
cerebral vessels, which may be remote from the site of
surgery.2
Outcome of craniocerebral aspergillosis is different in
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Table-1: Common clinical presentations.
Intracranial Disease
Headache 
Sensory impairment
Cranial nerve deficits
Vomiting
Seizures
Hemiparesis
Altered consciousness 
Paranasal Sinus Disease with Orbital Extension
Nasal stuffiness
Proptosis
Peri-orbital pain
Diplopia
Ophthalmoplegia
Visual deterioration
Chemosis
Figure: Algorithm for management of fungal lesions of the CNS.
immunosuppressed and apparently immunocompetent
hosts.32 In immunocompromised hosts mortality is reported
to reach more than 95%, and even 100 % in patients with
underlying malignancies.33 In apparently immunocompetent
hosts reported mortality varies from centre to centre, but
ranges from 40 to 80%.2 Patients harbouring mainly
sinonasal disease with only orbital and/or cranial base bony
invasion/destruction, carry a very good prognosis (mortality
< 20%).4 Outcome in extradural aspergillosis is much better
than in patients with intracerebral involvement and outcome
is worse in patients with intraparenchymal disease especially
with vascular invasion.2
Our centre deals with a large volume of patients with
isolated sinonasal aspergillosis, mainly catered by the
otorhinolaryngologists.34 As mentioned previously, these
patients do extremely well with local clearance and
antifungal medications, with the main concern being local
recurrence. We also deal with a significant number of patients
with intracranial disease, both extradural and intradural.
Fortunately such patients are not so common.2 Newer reports
are strongly suggesting improved outcome with pre-
medication prior to surgery have also emerged.35
Patients with extradural disease also do reasonably
well with local debridement (whenever feasible) along with
antifungal medications, the main risk being vascular invasion
and dural breach, both of which greatly affect outcome. These
patients are managed by the otorhinolaryngologists and
neurosurgeons together, at times both operating at the same
time. The most challenging group of patients remain the very
few who harbour intracranial intradural disease. These
patients are managed mainly by the neurosurgery team with
assistance from otorhinolaryngologists. The input of ther
specialties such as infectious disease experts,
endocrinologists, microbiologists and intensivists is also of
paramount importance. 
Our institute is a tertiary care facility catering to an
estimated population of 20 million. Over the past eight years,
we have operated upon 17 patients with intracranial
intradural aspergillosis. Of these 14 were males and 3 were
females; the mean age of these patients was 37 ± 17 years (2-
74 years) and the mean duration of symptoms was 3 ± 2
months (range 2 weeks to 6 months). All but three of these
patients were immunocompetent, two patients suffering from
haematological malignancies and one patient being a
diabetic. The disease mainly involved temporal lobes in
majority of patients (9 of 17). Pre-operative diagnosis of
aspergillosis was suspected in 14 of these patients, based on
clinical and radiological features, of which 13 received pre-
operative antifungal medications. In five patients either the
patient's condition or the extent of disease precluded radical
resection and these patients underwent minimally invasive
biopsies (3 patients), external ventriculostomy (one patient)
or burr hole aspiration of abscess (one patient). All the rest of
12 patients underwent radical surgeries aimed at removing
entire disease load. All patients were started on high dose
antifungal medications post-operatively. At mean follow up
of 5 months, all patients managed with minimally invasive
biopsy and chemotherapy and half of patients managed with
radical surgery along with chemotherapy expired. However,
6 of the 12 patients managed with radical surgery were still
alive, all with good outcomes, four having a Glasgow
Outcome Score (GOS) of 5 and two having a GOS of 4. Pre-
operative neurological status was the single most significant
indicator of poor outcome although none of the other factors
such as age of patient, duration of symptoms, extent of
disease or pre-operative administration of antifungal
medications could be shown to affect the outcome, perhaps
due to the small sample size.
Conclusion
Aspergillus infection of the CNS is an uncommon
clinical entity, affecting mainly the immunocompromised.
The disease presents in a number of unusual ways and
although a multitude of clinical, biochemical and radiological
features have been described, the diagnosis remains elusive.
The problem is further compounded when the host is
apparently immunocompetent, which lowers the clinical
suspicion. Radical surgery followed by systemic antifungal
medications offers the best hope for survival. Despite better
understanding of the offending organism, pathophysiology,
clinical course, and development of more effective antifungal
medications, the prognosis remains poor. High index of
suspicion, early diagnosis and aggressive surgical
management, followed by medical therapy, by an inter-
disciplinary team, may help to improve outcomes.
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